Clomiphene Interactions: Alcohol, Caffeine, Food and Other Compounds

What "interaction" means in the clomiphene literature

The word interaction covers several different research designs, and the clomiphene literature contains examples of only some of them. A pharmacokinetic interaction study measures whether one substance changes the absorption, distribution, metabolism or elimination of another. A pharmacodynamic interaction study measures whether two substances change each other's biological effect at the target. A clinical co-treatment trial simply gives two things together and measures an outcome, without separating the mechanism. For clomiphene, the published record is strongest for clinical co-treatment trials, moderate for computational pharmacokinetic modelling, and largely absent for the everyday combinations people ask about most — alcohol and caffeine.

This page reports what the identified studies actually examined. Where no interaction study exists, that gap is stated plainly, and the mechanistic reasoning researchers use in its place is labelled as reasoning rather than evidence. Background on the compound itself is covered in the clomiphene overview.

The pharmacokinetic starting point

Any interaction discussion begins with how a compound is handled by the body. Researchers constructed physiologically based pharmacokinetic (PBPK) models of (E)-clomiphene and its metabolites specifically to predict drug–drug–gene interaction scenarios, meaning situations where a co-administered drug, a genetic variant affecting a metabolising enzyme, or both together could shift exposure (PMID 36559098). That modelling work is important context because it treats clomiphene not as a single molecule but as a parent compound plus active and detectable metabolites whose relative concentrations can move independently.

The metabolite picture continued to expand. A 2023 analytical study identified and synthesised (Z)-3'-hydroxy clomiphene as a new potential doping-relevant metabolite, showing that clomiphene's metabolic fate was still being characterised well after the parent compound entered clinical use (PMID 37580503). For interaction research this matters: if a co-ingested substance altered metabolite formation, the analytical signature — not just the clinical effect — could change.

Clomiphene and Alcohol: What Studies Report

No verified human trial in this citation set administered clomiphene together with alcohol and measured the result. That is the single most important statement in this section, and nothing below should be read as filling that gap.

What the literature does contain is a set of animal models in which ethanol itself was the insult under study. One rodent study examined Carica papaya as an intervention against testicular histomorphological and hormonal alterations following alcohol-induced gonadotoxicity in male rats, establishing that ethanol exposure produced measurable changes in testicular structure and hormone profiles in that model (PMID 32257927). A separate study investigated the effect of Rourea coccinea on ethanol-induced male infertility in Wistar albino rats, again using ethanol as the experimental cause of reproductive impairment (PMID 33756034).

These are ethanol toxicology studies in rats, not clomiphene interaction studies in humans. They establish that ethanol has been reported to disturb male reproductive endpoints in animal models (PMID 33756034), which is why investigators in the male fertility field treat alcohol exposure as a variable worth controlling. Labelled as mechanistic reasoning, not evidence: because ethanol is hepatically metabolised and because clomiphene exposure is modelled as sensitive to co-administered substances and enzyme genotype (PMID 36559098), researchers describe a theoretical overlap at the level of hepatic handling — but no study in this set tested it.

Clomiphene and Caffeine: what the evidence does and does not cover

There is no identified study, in this verified set, that administered caffeine and clomiphene together and measured pharmacokinetics, hormone levels or clinical outcomes. No dose, no timing relationship and no effect size can be reported, because none was measured.

What researchers do instead is reason from metabolism. Labelled as mechanistic reasoning: caffeine and clomiphene are handled by different principal cytochrome P450 routes, and the formal way to test whether a shared route matters is the kind of drug–drug–gene simulation built for (E)-clomiphene and its metabolites (PMID 36559098). Such modelling can flag which co-substrates deserve a real clinical study; it does not substitute for one. Readers encountering confident claims about caffeine and clomiphene should note that the underlying experiment has not been published in the literature surveyed here.

Food, fasting and dietary exposure

No dedicated food-effect study — the standard fed-versus-fasted crossover design used in pharmacokinetics — appears in this verified set for clomiphene, so no statement can be made about whether meals change its absorption profile.

Food does appear in the clomiphene literature from an unexpected angle. Researchers assessed human urinary clomiphene metabolites after volunteers consumed eggs from clomiphene-treated laying hens, using chromatographic–mass spectrometric approaches, and the study reported that dietary exposure of this kind could be reflected in human urinary metabolite profiles (PMID 35341524). That work was designed around anti-doping interpretation rather than therapeutics, but it demonstrates a food-related route of measurable exposure that pure pharmacology discussions often omit. It pairs naturally with the metabolite identification work on (Z)-3'-hydroxy clomiphene, since both concern what analytical testing can detect and attribute (PMID 37580503).

Clomiphene combined with other compounds in clinical trials

Unlike alcohol and caffeine, several deliberate clinical combinations have been trialled.

With letrozole

An open-label randomised controlled trial compared letrozole alone versus a combination of letrozole and clomiphene citrate for ovulation induction in subfertile women with polycystic ovary syndrome, with the study reporting ovulation and pregnancy outcomes across the two arms (PMID 39500849). This is a pharmacodynamic combination at the level of the hypothalamic–pituitary–ovarian axis rather than a metabolic interaction.

With antioxidants

In male infertility research, a randomised controlled trial evaluated combination clomiphene citrate and antioxidant therapy for idiopathic male infertility, and researchers reported semen parameter and pregnancy outcomes for the combination compared with control (PMID 19268928). A broader review of medical treatments for male infertility placed such hormonal and adjunctive strategies in context, describing where evidence was considered adequate and where it was not (PMID 38012910).

With non-pharmacological co-treatments

A randomised clinical trial published in JAMA examined acupuncture and clomiphene in Chinese women with polycystic ovary syndrome, using a design that allowed the contribution of each to be assessed, with live birth as the reported outcome (PMID 28655015). The trial illustrates how co-treatment questions are formally tested rather than assumed.

Within treatment algorithms

Guideline and review literature addresses where clomiphene sits relative to other agents and procedures. A guideline on evidence-based treatments for couples with unexplained infertility summarised the evidence for oral agents used alongside insemination and other interventions (PMID 32106976), while a review on optimizing the first-line fertility treatment discussed how first-line oral options were compared in the published trials (PMID 29463146).

Outside reproduction

Clomiphene has also appeared in unrelated screening work: an in vitro study reported that several FDA-approved drugs, clomiphene among the compounds screened, inhibited SARS-CoV-2 infection in cell culture (PMID 33613282). Cell-culture screening is not an interaction study and does not describe behaviour in people.

Summary table of what was and was not examined

Interaction-Related Adverse Events: What Studies Report

Adverse-event reporting in this literature is tied to the specific trial designs rather than to interaction experiments. The randomised clinical trial of acupuncture and clomiphene in women with PCOS collected adverse event data alongside its live birth outcome (PMID 28655015), and the open-label randomised trial comparing letrozole with the letrozole plus clomiphene citrate combination reported outcomes for both arms in subfertile women with PCOS (PMID 39500849). Review-level sources in male infertility discussed the tolerability and evidence quality of medical treatments in that setting (PMID 38012910).

No adverse event in this set has been attributed to co-ingestion of alcohol or caffeine with clomiphene, because no study in this set created that exposure. Absence of reported harm from an experiment that was never run is not a finding about harm.

How to read the gaps

• Modelling is a hypothesis generator. PBPK simulation of (E)-clomiphene identified drug–drug–gene scenarios worth testing; it did not measure them in participants (PMID 36559098).
• Animal toxicology is about the toxin studied. The ethanol rat models describe ethanol's effects on reproductive tissue, not a combined exposure (PMID 32257927).
• Detection studies are not clinical studies. The egg-consumption work measured urinary metabolites for analytical interpretation (PMID 35341524).
• Co-treatment trials answer outcome questions, not mechanism questions. Combination trials with letrozole and with antioxidants reported clinical endpoints rather than pharmacokinetic ones (PMID 39500849, PMID 19268928).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, combination or health decision. Nothing here describes a protocol, and no combination discussed above is characterised as appropriate or inappropriate for any individual.

References

• Prediction of Drug-Drug-Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling (Pharmaceutics, 2022)
• Identification and synthesis of (Z)-3'-hydroxy clomiphene as a new potential doping-relevant metabolite of clomiphene (Rapid Communications in Mass Spectrometry, 2023)
• Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches (Analytica Chimica Acta, 2022)
• Carica papaya attenuates testicular histomorphological and hormonal alterations following alcohol-induced gonado toxicity in male rats (Toxicological Research, 2020)
• Effect of Rourea coccinea on ethanol-induced male infertility in Wistar albino rats (Andrologia, 2021)
• Comparison of Letrozole Versus Combination Letrozole and Clomiphene Citrate (CC) for Ovulation Induction in Sub Fertile Women with Polycystic Ovarian Syndrome (PCOS)-An Open Label Randomized Control Trial (Reproductive Sciences, 2024)
• Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial (JAMA, 2017)
• Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial (Fertility and Sterility, 2010)
• [Medical treatments for male infertility] (Progrès en Urologie, 2023)
• Evidence-based treatments for couples with unexplained infertility: a guideline (Fertility and Sterility, 2020)
• Optimizing the first-line fertility treatment (Gynecological Endocrinology, 2018)
• Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro (Frontiers in Pharmacology, 2020)